PDL BioPharma has reported a net income of $48.57m, or $0.32 per diluted share, for the third quarter ended 30 September 2012 compared to $45.92m, or $0.28 per diluted share, for the third quarter ended 30 September 2011.
Total revenues for third quarter of 2012 were $85.23m compared to $83.77m for the third quarter of 2011.
The company reported a net income of $162.26m, or $1.08 per diluted share, for the nine months ended 30 September 2012 compared to a net income of $160.45m, or $0.88 per diluted share, for the nine months ended 30 September 2011.
Total revenues of $288.48m were reported for the first nine months of 2012 compared to $289.23m for the first nine months of 2011.
PDL BioPharma has announced that the increase in royalty revenues by 2% are based on second quarter 2012 product sales by its licensees.
